California AG Files Suit Seeking $20 Million Penalties on Two Nonprofits Over Abortion Pill Reversal Claims

The June 2024 trial centers on claims that the nonprofits misled women about the safety and efficacy of progesterone protocols after mifepristone ingestion. Court records show the state issued subpoenas and operated a complaint portal yet produced no individual complainants alleging injury. The organizations documented seven women who completed reversals successfully and plan to testify. This action follows Dobbs and aligns with state statements targeting crisis pregnancy centers as part of post-decision enforcement priorities.

Primary documents reveal the state frames the speech as deceptive commercial conduct under consumer protection statutes. The nonprofits operate without charge and provide referrals to licensed physicians. No statute criminalizes the underlying medical information exchange. Discovery yielded no epidemiological data linking the organizations' materials to adverse outcomes, shifting the dispute to contested studies on reversal rates rather than proven misrepresentation.

The litigation tests state authority to designate one side of an evolving medical protocol as the sole permissible viewpoint. Comparable regulatory actions in other jurisdictions have targeted both pro-choice and pro-life actors when speech conflicted with prevailing agency positions. California gains narrative control over abortion access messaging; the cost includes exposure to First Amendment challenges that could constrain future enforcement in adjacent health policy domains.

If the court imposes the requested fines, similar actions may expand to other states citing the precedent. A defense verdict would require the state to demonstrate actual consumer deception thresholds before restricting nonprofit medical speech.